Before the introduction of new therapeutic agents, such as immune checkpoint inhibitors (ICIs) and
BRAF/MEK inhibitors, the median overall survival (OS) of patients with advanced melanoma was less than a year with only 1 in 10 patients surviving more than 5 years.
1 The introduction of these new systemic treatments has significantly improved the prognosis of patients with advanced melanoma.
2 Durable responses reported in clinical trials were also observed in patients treated in clinical practice.
3,4 Ipilimumab, a monoclonal antibody blocking
CTLA-4, was introduced in 2012 and was the first registered ICI for the treatment of advanced melanoma.
5 Antibodies that target programmed cell death (anti–PD-1) were introduced in 2015, and the combination of ipilimumab and nivolumab in 2016.
6,7 Targeted therapies, such as
BRAF inhibitor therapies, were introduced in 2012, whereas
MEK inhibitors were introduced in 2016 in the Netherlands.
8,9